Minerva Imaging

Minerva Imaging is a Danish contract research and development organisation specialising in targeted radiopharmaceuticals and translational research within oncology and cardiovascular diseases.

Founded in 2011 and headquartered in Denmark, Minerva Imaging is a science-driven Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CDMO) with a strong focus on molecular imaging and targeted radioligand therapy. The company supports preclinical and early clinical drug development by integrating expertise in disease biology, imaging technologies, and radiochemistry. With an emphasis on oncology and cardiovascular disease, Minerva collaborates with pharmaceutical and biotech companies globally to advance therapeutic innovation from research to clinic.

The company has built a robust infrastructure that combines advanced imaging modalities, radiopharmaceutical production capabilities, and in vivo disease models to offer fully integrated, end-to-end services. Minerva’s team of over 150 employees, including a large proportion of PhD-level scientists, work across dedicated facilities that support both discovery and regulatory-grade studies. The company is GLP and GMP certified, with a radiopharmaceutical manufacturing facility approved by the Danish Medicines Agency.

Key Products and Services:

Radiopharmaceutical CDMO services, including GMP manufacturing of radiotracers

Preclinical imaging (PET, SPECT, CT, MRI, ultrasound)

In vivo efficacy and biodistribution studies

Tumour and cardiovascular disease models

Dosimetry and bioanalysis

Regulatory support for early clinical trials

Customised translational research programmes

Access to a fully equipped vivarium and imaging infrastructure

Minerva Imaging has positioned itself as a trusted partner in the fast-evolving field of radiopharmaceuticals by combining deep scientific expertise with operational excellence. Through its integrated CRO and CDMO platform, the company plays a pivotal role in helping drug developers bring targeted therapies to patients faster and more efficiently.